4 news items
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
URGN
5 May 24
therapy (n=53), JELMYTO was associated with an 86% recurrence-free survival rate at 24 months across diverse patient types regardless of initial disease
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
URGN
4 May 24
and other complications from JELMYTO use in diverse UTUC patient types; the ability to maintain regulatory approval; the ability to obtain and maintain
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
URGN
17 Apr 24
related to JELMYTO treatment of LG-UTUC patients in a diverse patient types."
Key details of UGN-102
NorthStar Appoints Peter Pfreundschuh to Board of Managers
URGN
VYGR
15 Apr 24
, the opportunities are enormous and having strong board members with a wealth of diverse, deep industry experience will help us unlock the promise
- Prev
- 1
- Next